17:17 EST 22nd November 2017 | BioPortfolio

A next-generation GC-C agonist, SP-333, is being developed for the treatment of opioid-induced constipation (OIC) and mild-to-moderate ulcerative colitis (UC).

Superior stability and a novel mechanism-of-action, combined with a unique formulation, open the possibility for SP-333 to provide a new way to treat patients with OIC and mild-to-moderate UC.

Status of SP-333 Clinical Programs

  • First phase 1 single-dose, dose-escalation trial in healthy volunteers completed in December 2012
  • Multiple-ascending dose phase 1b trial in healthy volunteers completed in July 2013
  • Initiated SP-333 phase 2 study in patients with OIC in October 2013
  • Formulation development of SP-333 to treat UC is currently underway


Quick Search

review and buy SP-333 market research data and corporate reports here